Progyny's stock surged 14.82% in pre-market trading following the release of its first-quarter 2026 financial results that significantly exceeded analyst expectations and an upward revision to its full-year guidance.

The women's health benefits provider reported adjusted earnings per share of $0.50 for Q1 FY26, beating the consensus estimate of $0.30 by a substantial margin. Revenue of $328.5 million also came in above expectations of $326.57 million. The company's net income saw a significant year-over-year increase, while gross margin expanded, reflecting ongoing efficiencies in care management.

Adding to the positive investor sentiment, Progyny raised its full-year adjusted EPS outlook and provided second-quarter revenue and adjusted EBITDA guidance that surpassed analyst estimates. The company cited robust demand for women's health and family building solutions, with early selling season activity and higher member engagement driving growth despite macroeconomic uncertainty.